Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06834451 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06834451 · ClinicalTrials.gov record · last posted 2025-06-19

Bioequivalence Study of Revolade® Eltrombopag 50 mg

Study acronym: Eltrombopag
StatusActive, Not Recruiting
PhasePhase 4
Started2025-06-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 19, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
Bioequivalence Study

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2025-02-13. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-06-16
Status change Not Yet Recruiting→Active, Not Recruitingv1
Trial Details
NCT Number NCT06834451
Lead Sponsor Centro de Atencion e Investigacion Medica
Conditions Healthy, Healthy Donors
Enrollment 30 participants
Start Date 2025-06-01
Primary Completion 2025-10-30 (estimated)
Study Completion 2025-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-19